Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. - Wikidata - awgldk - TriplyDB

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.

http://www.wikidata.org/entity/Q33767727

about

Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection CCR9 in cancer: oncogenic role and therapeutic targeting Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency Protein deimmunization via structure-based design enables efficient epitope deletion at high mutational loads Antibody humanization by structure-based computational protein design.Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors.Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy Targeted diphtheria toxin to treat BPDCN.Progress and prospects of gene therapy clinical trials for the muscular dystrophies.Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance.Furin-dependent CCL17-fused recombinant toxin controls HTLV-1 infection by targeting and eliminating infected CCR4-expressing cells in vitro and in vivo.Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A.EpiSweep: Computationally Driven Reengineering of Therapeutic Proteins to Reduce Immunogenicity While Maintaining Function.Immunoconjugates in the management of hairy cell leukemia.Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity.A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice Immunogenicity of therapeutic recombinant immunotoxins.Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead.The future of antiviral immunotoxins.Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.Design and engineering of deimmunized biotherapeutics.Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer.A novel immunotoxin - rCCK8PE38 targeting of CCK-R overexpressed colon cancers.Bioinformatic prediction and experimental validation of a PE38-based recombinant immunotoxin targeting the Fn14 receptor in cancer cells.Clinical targeting recombinant immunotoxins for cancer therapy Immunity to CRISPR Cas9 and Cas12a therapeutics.GradDock: Rapid Simulation and Tailored Ranking Functions for Peptide-MHC Class I Docking.Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity.Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.Improving the in vivo efficacy of an anti-Tac (CD25) immunotoxin by Pseudomonas exotoxin A domain II engineering.

P2860

Q27005830-689C7B50-E486-459C-A297-1DF179931BEF Q28066712-A83E26BB-8D3F-4698-B780-A965620143CA Q28546010-4D732C83-EBB0-4832-A78E-B1BD4903C34D Q30371474-0C6720DA-0711-4FB3-9937-90728E6626D3 Q30377654-AFE54B39-323F-45D3-A48E-7A008887E0D7 Q30847784-9210DE81-24A1-47D8-AE78-DCD98ED0B5AC Q33652098-92B217BE-F237-428C-9DB9-2B4585F26EDB Q33779122-0C0ADF5F-C617-4C69-92F8-847D6B298E88 Q33917153-7A733421-02AC-439B-95DB-F57C309BB8EF Q34497471-161FD507-01A8-4674-A21B-A9743F96A986 Q35170403-F66EC828-F6D8-48E6-96AE-BEF7E219367A Q35638576-805807E2-7BB7-4473-946E-2FEEA1D900D9 Q35751036-9CD59C9F-086A-4D4D-BD11-F45D83C2AD6C Q35984815-E7C49464-A284-41DD-A6A3-7AB82A100784 Q36157120-B54B4A08-C4F8-48D6-A58D-1703657327BD Q36212517-358B390A-30A7-49DB-849C-75FF413921D6 Q36328016-E2C3E535-798C-41FA-B894-2F7151D3B16B Q36359728-7F3112D5-3A43-40B5-A421-92A2B54B5F59 Q36399908-1B40EC28-9991-4BDE-98B4-35BEC7273800 Q36470281-ED3CA7AB-C65F-4200-9ACB-A43978E8BC07 Q36593468-6FF36214-01D7-4265-99D9-D36A4797B661 Q37209001-450DC142-D452-4787-9105-C453F8074A0E Q37327375-058EEA5B-63E6-4071-87F0-0A909D5C1824 Q37367958-663E9035-4AF2-4954-A9F8-4D72506003B2 Q38686601-9569410D-BDE9-4D32-A50C-82BE870A8664 Q38721404-B2EAD97F-A5C5-4EF5-B785-286577CA5F08 Q38778443-02426421-F0B2-4D27-8CD0-A9ED96A1C435 Q38870681-000A386D-EB82-4F92-8164-4BF05EFEF464 Q38885212-20FF8A24-CE8E-4DAA-AD88-404686F2E61A Q38896408-9C8D56D1-EBD1-4297-A257-FE2BA22C8A01 Q38910559-9F8C215B-B6BC-4CA1-84D1-5BAE55CA68CC Q40267233-A7663451-12AB-41BC-BC5D-7C6D832BF719 Q41149227-3CACFE74-1F0D-4DA7-8E81-560246BCF3E9 Q45873745-60101FBB-1C82-4237-A13B-236FB6A0E558 Q47317031-30BDB101-1712-4049-A11E-7CE01753E3F0 Q47716213-68C02F04-4219-44CD-BBFF-291CA4EB94C8 Q50962872-B6859875-AA56-48CC-BD08-2613277CB30B Q51602149-D124FC99-AFC5-44CE-944F-8902E73E3500 Q52716628-C216BEE1-9121-4FB5-8E55-737AC12354CF

P2860

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.

http://www.wikidata.org/entity/Q33767727

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Recombinant immunotoxin for ca ...... cing of human T-cell epitopes.

@ast

Recombinant immunotoxin for ca ...... cing of human T-cell epitopes.

@en

type

label

Recombinant immunotoxin for ca ...... cing of human T-cell epitopes.

@ast

Recombinant immunotoxin for ca ...... cing of human T-cell epitopes.

@en

prefLabel

Recombinant immunotoxin for ca ...... cing of human T-cell epitopes.

@ast

Recombinant immunotoxin for ca ...... cing of human T-cell epitopes.

@en

P1433

Q33767727-CA2F9789-6D8B-4C0C-A3DC-BCDC41CF9AC0

P1476

Q33767727-448A2421-3E98-482A-8B9B-28C03D017E10

P2093

Q33767727-3B2FC01F-D741-4C12-835F-225E3844AF54

Q33767727-6DBCEDA2-73B4-46A2-92F9-F517FC974AAB

Q33767727-741235CB-FD98-4490-8224-E87392956124

Q33767727-80F1B888-F451-4844-975E-EEAC4ADE3E8E

Q33767727-83125727-4BEA-4FE3-A8D6-C5FF3F6D442B

Q33767727-84922DCB-7AA7-4D0B-BEC9-6B5F2C48A2DC

Q33767727-9137479D-B85A-425A-879C-286B000566D3

Q33767727-91FBC13D-D426-4BEE-B4D3-C3197ACD2F28

Q33767727-C7C077B0-EE4F-4B99-BC94-B193DAD2C340

Q33767727-D16E953D-4D16-4389-8C38-77CE1911ADED

P2860

Q33767727-07566DDA-89A1-4220-B776-8F2400861963

Q33767727-08289790-B8FC-4CC6-AA09-2EE5EA86CCE3

Q33767727-0BCD66B7-919D-44B1-9605-E7E83DE8344D

Q33767727-127E500A-AEDC-4E4B-A059-21940433BC88

Q33767727-1A134FA5-B759-432F-8E71-F94CDE2BD91B

Q33767727-1DBE2651-FAB7-4B60-B60F-7453892E1B40

Q33767727-1F1E5D97-4A88-45B9-99C6-0D14F062A1F0

Q33767727-208F3C27-89B0-4A4B-823B-EBC3C7C316FF

Q33767727-24EE6534-50CB-42D2-BACA-9A44AA3AB965

Q33767727-33D77FDF-E5CB-4ECB-BA5A-97321C02B952

P304

Q33767727-456597A0-206E-4250-87F3-414309D8A9F4

P31

Q33767727-1D60A48A-CAFA-4033-B435-C5AA288CCD0D

P356

Q33767727-A5D60288-A78D-450A-BD27-2BF3879161FD

P407

Q33767727-EF684799-7DA3-423E-A7B7-ED45EDEA9469

P433

Q33767727-06A854F9-FFBE-4C0B-A234-41660378C080

P478

Q33767727-F6F2BD82-A458-42AD-BB70-D304FB5DE076

P50

Q33767727-3C26A443-7C51-4570-AE45-529D9A6E6CDC

Q33767727-D575DAAC-AAAA-45C4-B89F-C8FA640C3489

P577

Q33767727-D622224C-6553-45C3-8E59-481DF0675A4F

P5875

Q33767727-C08D1F1C-DCF2-4205-912B-716568700730

P698

Q33767727-3430D727-9CD4-4CA7-B43F-FC53CA3C8A25

P932

Q33767727-BBEFC5FE-C901-49CA-AF0B-8F74CAB7C611

P356

PNAS.1405153111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Recombinant immunotoxin for ca ...... cing of human T-cell epitopes.

@en

P2093

Aaron N Vassall

http://www.w3.org/2001/XMLSchema#string

Byungkook Lee

http://www.w3.org/2001/XMLSchema#string

Chris King

http://www.w3.org/2001/XMLSchema#string

Elizabeth C Lee

http://www.w3.org/2001/XMLSchema#string

Ira Pastan

http://www.w3.org/2001/XMLSchema#string

Jaime A Eberle

http://www.w3.org/2001/XMLSchema#string

Masanori Onda

http://www.w3.org/2001/XMLSchema#string

Raffit Hassan

http://www.w3.org/2001/XMLSchema#string

Richard Beers

http://www.w3.org/2001/XMLSchema#string

Robert J Kreitman

http://www.w3.org/2001/XMLSchema#string

P2860

Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity

The interpretation of protein structures: estimation of static accessibility

Immunogenicity of protein therapeutics

Removing T-cell epitopes with computational protein design.

Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution

Improving antibody affinity by mimicking somatic hypermutation in vitro.

A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach

Peptide binding predictions for HLA DR, DP and DQ molecules

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.

T cell-dependent B cell activation.

P304

8571-8576

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1405153111

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262076415

http://www.w3.org/2001/XMLSchema#string

P698

24799704

http://www.w3.org/2001/XMLSchema#string

P932

4060717

http://www.w3.org/2001/XMLSchema#string